Your browser doesn't support javascript.
loading
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain / Estudio en el mundo real sobre patrones de prueba de inestabilidad de microsatélites y deficiencia de reparación de desajustes en pacientes con cáncer colorrectal metastásico en España
Garcia-Carbonero, Rocio; González Astorga, Beatriz; Vidal Tocino, Rosario; Contreras Toledo, Débora; Pericay, Carles; Fernández Montes, Ana; Falcó, Esther; González Cordero, Marta; Reina Zoilo, Juan José; Alonso, Vicente.
  • Garcia-Carbonero, Rocio; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • González Astorga, Beatriz; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Vidal Tocino, Rosario; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Contreras Toledo, Débora; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Pericay, Carles; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Fernández Montes, Ana; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Falcó, Esther; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • González Cordero, Marta; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Reina Zoilo, Juan José; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
  • Alonso, Vicente; Hospital Universitario 12 de Octubre. Medical Oncology Department. Madrid. Spain
Clin. transl. oncol. (Print) ; 26(4): 864-871, Abr. 2024. tab
Article En | IBECS | ID: ibc-VR-49
: ES1.1
: ES15.1 - BNCS

Purpose:

Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers.

Methods:

Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages.

Results:

Three hundred patients were included in the study from May 2020 through May 2021, with a median age of 68 years, and two hundred twenty-five (75%) had stage IV disease at initial diagnosis; two hundred eighty-four patients received first-line treatment, and dMMR/MSI-H testing was performed in two hundred fifty-one (84%) patients. The results of the dMMR/MSI-H tests were available in 61 (24%) of 251 patients before the diagnosis of metastatic disease and in 191 (81%) of 236 evaluable patients for this outcome before the initiation of first-line treatment. Among the 244 patients who were tested for dMMR/MSI-H with IHC or PCR, 14 (6%) were MMR deficient. The most frequent type of first-line treatment was the combination of chemotherapy and biological agent, that was received by 71% and 50% of patients with MMR proficient and deficient tumors, respectively, followed by chemotherapy alone, received in over 20% of patients in each subgroup. Only 29% of dMMR/MSI-H tumors received first-line immunotherapy.

Conclusion:

Our study suggests that a high proportion of patients with mCRC are currently tested for dMMR/MSI-H in tertiary hospitals across Spain. However, there is still room for improvement until universal testing is achieved.(AU)


...